Category: Enlivex

EF Hutton has affirmed its Buy rating on shares of Enlivex Therapeutics (NASDAQ: ), with a $13.00 price target. The firm’s stance comes in light of Enlivex’s recent announcement regarding the progress of its clinical trial for knee osteoarthritis. The Danish Medicines Agency has granted the company permission to start…